KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $54.1 million.

  • Amneal Pharmaceuticals' Depreciation & Amortization (CF) fell 8.29% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.5 million, marking a year-over-year increase of 5.94%. This contributed to the annual value of $236.2 million for FY2024, which is 2.96% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $54.1 million for Q3 2025, which was down 10.05% from $60.1 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $66.1 million for Q4 2024, and its period low was $54.1 million during Q3 2025.
  • Over the past 3 years, Amneal Pharmaceuticals' median Depreciation & Amortization (CF) value was $57.2 million (recorded in 2023), while the average stood at $58.2 million.
  • In the last 5 years, Amneal Pharmaceuticals' Depreciation & Amortization (CF) grew by 16.15% in 2024 and then fell by 8.29% in 2025.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Depreciation & Amortization (CF) stood at $61.2 million in 2021, then fell by 0.21% to $61.1 million in 2022, then decreased by 6.75% to $56.9 million in 2023, then increased by 16.15% to $66.1 million in 2024, then declined by 8.29% to $54.1 million in 2025.
  • Its last three reported values are $54.1 million in Q3 2025, $60.1 million for Q2 2025, and $60.2 million during Q1 2025.